Shots:

• Vir and NIAID will jointly identify and optimize combinations of Ab against coronaviruses- including SARS-CoV-2- SARS- and MERS along with Ab that may show effectiveness across additional types of coronaviruses
• The collaboration allows Vir to access VRC’s research experience with coronaviruses to accelerate the development of Ab targeting the unmet medical needs of patients
• Vir has identified several mAbs that bind to SARS-CoV-2 and were isolated from individuals who had survived a SARS infection. The company is evaluating Ab that it may be able to identify from COVID-19 survivors- can be effective as treatment and/or prophylaxis against SARS-CoV-2

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: PRNewswire